Could Resveratrol Help Slow The Progression of Alzheimer's Disease?
In patients with Alzheimer’s disease (AD), administration of high-dose oral resveratrol (RES) successfully stabilized amyloid-beta 40 (Aβ40) in plasma and cerebrospinal fluid (CSF), according to a recent study.
For the phase 2 study (a 12-month trial), participants were randomly assigned 500 mg (once daily: N=64)) of oral RES once daily, then escalated to 1000 mg twice daily at 13-week intervals, or placebo (n=55).
__________________________________________________________________________________________________________________________________________________________________
RELATED CONTENT
Could Grapes Help Fight Acne?
1 in 3 Cases of Alzheimer's Preventable
__________________________________________________________________________________________________________________________________________________________________
Researchers used the Mini Mental State Examination to determine the participants’ progression of AD. According to researchers, all of the participants’ plasma Aβ40 levels, brain volume measurements, and cognitive test and performance scores were similar.
The study showed that RES treatment altered Aβ40 levels is CSF and plasma, but had no impact on hippocampal volume, entorhinal cortex thickness, or CSF tau or phosphor-tau-181. The secondary outcomes were not impacted either.
“Resveratrol crossed the blood brain barrier and altered the levels of Abeta40 in plasma and CSF. Given its safety, ability to enter the central nervous system, and its biomarker effects, further studies of resveratrol are warranted,” they concluded.
The complete study was presented at the 7th Clinical Trials Conference on Alzheimer’s disease (CTAD).
-Michelle Canales
Reference:
Turner RS, Thomas RG, Craft S, et al. OC2. Resveratrol is safe and well-tolerated and stabilizes plasma and CSF A40 levels in mild-moderate AD. Paper presented at: 7th Clinical Trials Conference on Alzheimer’s disease (CTAD); November 20, 2014; Philadelphia, PA.